- Home
- CELC vs LXFR Comparison
CELC vs LXFR Comparison
Compare CELC & LXFR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CELC
- LXFR
- Stock Information
- Founded
- CELC 2011
- LXFR 1898
- Country
- CELC United States
- LXFR United States
- Employees
- CELC N/A
- LXFR N/A
- Industry
- CELC Medical Specialities
- LXFR Major Chemicals
- Sector
- CELC Health Care
- LXFR Industrials
- Exchange
- CELC Nasdaq
- LXFR Nasdaq
- Market Cap
- CELC 327.3M
- LXFR 380.9M
- IPO Year
- CELC 2017
- LXFR 2012
- Fundamental
- Price
- CELC $10.24
- LXFR $9.85
- Analyst Decision
- CELC Strong Buy
- LXFR
- Analyst Count
- CELC 6
- LXFR 0
- Target Price
- CELC $30.17
- LXFR N/A
- AVG Volume (30 Days)
- CELC 392.7K
- LXFR 134.1K
- Earning Date
- CELC 05-14-2025
- LXFR 04-29-2025
- Dividend Yield
- CELC N/A
- LXFR 5.27%
- EPS Growth
- CELC N/A
- LXFR N/A
- EPS
- CELC N/A
- LXFR 0.68
- Revenue
- CELC N/A
- LXFR $391,900,000.00
- Revenue This Year
- CELC N/A
- LXFR $2.26
- Revenue Next Year
- CELC N/A
- LXFR $5.85
- P/E Ratio
- CELC N/A
- LXFR $14.49
- Revenue Growth
- CELC N/A
- LXFR N/A
- 52 Week Low
- CELC $7.58
- LXFR $9.26
- 52 Week High
- CELC $19.77
- LXFR $15.64
- Technical
- Relative Strength Index (RSI)
- CELC 54.38
- LXFR 32.39
- Support Level
- CELC $7.58
- LXFR $9.41
- Resistance Level
- CELC $10.48
- LXFR $10.80
- Average True Range (ATR)
- CELC 1.04
- LXFR 0.60
- MACD
- CELC 0.17
- LXFR -0.01
- Stochastic Oscillator
- CELC 80.01
- LXFR 16.99
About CELC Celcuity Inc.
Celcuity Inc is a clinical-stage biotechnology company pursuing development for oncology. The Company's lead therapeutic candidate is gedatolisib, a potent pan-PI3K and mTOR inhibitor. Its mechanism of action and pharmacokinetic properties are highly differentiated from other currently approved and investigational therapies that target PI3K or mTOR alone or together. A Phase 3 clinical trial, VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast cancer is currently enrolling patients.
About LXFR Luxfer Holdings PLC
Luxfer Holdings PLC is a manufacturer industrial company innovating niche applications in materials engineering. It focuses on value creation by using its broad array of technical know-how and proprietary technologies to help create a safe, clean, and energy-efficient world. Luxfer's high-performance materials, components, and high-pressure gas containment devices are used in defense, first response and healthcare, transportation, and general industrial applications. It focuses on product lines related to magnesium alloys, zirconium chemicals, and carbon composites. Its segments are Elektron, Gas Cylinders, and Graphic Arts. It generates the majority of its revenue from Elektron and as well as Gas Cylinders.